ロード中...
ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI), is used clinically as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) with EGFR activating mutations, but the inevitable development of acquired resistance limits its efficacy....
保存先:
| 出版年: | Front Pharmacol |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2018
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6256088/ https://ncbi.nlm.nih.gov/pubmed/30515095 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2018.01312 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|